Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial

Andrea Necchi(Vita-Salute San Raffaele University), Roberto Salvioni(Neurology, Inc), Salvatore Lo Vullo(Azienda Sanitaria Locale di Asti), Marzia Pennati(Fondazione IRCCS Istituto Nazionale dei Tumori), E. Togliardi(Fondazione IRCCS Istituto Nazionale dei Tumori), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Nicola Nicolai(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppina Calareso(Fondazione IRCCS Istituto Nazionale dei Tumori), Nadia Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Maurizio Colecchia, Patrizia Giannatempo(Fondazione IRCCS Istituto Nazionale dei Tumori), Luigi Mariani(Fondazione IRCCS Istituto Nazionale dei Tumori), Adele Busico(Fondazione IRCCS Istituto Nazionale dei Tumori), Flavio Crippa(National Cancer Institute), Federica Perrone(University of Bari Aldo Moro)
Annals of Oncology
March 16, 2017
10.1093/annonc/mdx124
Cited by 46

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k